Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

Belén Toledo,Chiara Deiana,Fabio Scianò,Giovanni Brandi,Juan Antonio Marchal,Macarena Perán,Elisa Giovannetti
DOI: https://doi.org/10.1080/17512433.2024.2319340
2024-03-16
Expert Review of Clinical Pharmacology
Abstract:Introduction Treatment resistance poses a significant obstacle in oncology, especially in biliary tract cancer (BTC) and pancreatic cancer (PC). Current therapeutic options include chemotherapy, targeted therapy, and immunotherapy. Resistance to these treatments may arise due to diverse molecular mechanisms, such as genetic and epigenetic modifications, altered drug metabolism and efflux, and changes in the tumor microenvironment. Identifying and overcoming these mechanisms is a major focus of research: strategies being explored include combination therapies, modulation of the tumor microenvironment, and personalized approaches.
pharmacology & pharmacy
What problem does this paper attempt to address?